Editorial & Letters

EDITORIAL Cell Biology of the Cytoskeleton

Cells come in a huge variety of shapes and sizes, from the almost spherical lymphocyte, to amoeboid cells such as macrophages, to flattened spindle-shaped fibroblasts or polygonal epithelial cells, to neuronal cells with the complex branching extensions the dendrites and the very long extension the axon. Such cellular architecture is constructed and maintained by the cytoskeleton, a dynamic network of intracellular proteinaceous structural elements. The cytoskeleton is responsible for cell shape, motility, migration, and polarity, and for establishing intercellular contacts to produce tissue architecture. In addition, the cytoskeleton plays many roles inside the cell. For example, in cell division it forms the scaffold on which chromosomes are segregated to daughter cells and separates the daughter cells after mitosis. Like the vertebrate skeleton, certain types of cytoskeletal elements are more or less permanent features of cells, including the actin and myosin filament bundles in muscle cells and the microtubule arrays in cilia and flagellae. Other cytoskeletal structures are very dynamic, continuously assembling and disassembling like the tracks of a child's train set as part of their functional cycle or for use in various cellular processes. One particularly radical example of cytoskeletal dynamics is the complete remodeling of the microtubule array of a cell during mitosis—it changes from a network radiating throughout the cell to the compact, bipolar, mitotic spindle.

In this special issue of Science, some of the emerging areas of research on cytoskeletal dynamics are examined. The basic building blocks of the cytoskeleton include actin microfilaments (about 7 nm in diameter), tubulin microtubules (about 24 nm in diameter), and a variety of intermediate filaments (about 10 nm in diameter). Each filament type is composed of linear polymers of globular protein subunits, which are assembled and disassembled by the cell in a carefully regulated fashion, sometimes at astonishing rates. One of the classical images of the cytoskeleton is the molecular machinery of muscle tissue, in which microfilament arrays are linked by myosin motor filaments, forming sliding filaments that expand and contract in generating force. Mermall and colleagues (p. 527) review the current state of knowledge about the roles of nonmuscle myosins, which do not form filamentous structures, in various cellular processes, including membrane traffic, cell movement, and signal transduction. Microtubules play fundamental roles in the formation of complex cellular geometries such as axons, the extremely elongated processes of neurons. Microtubule-based motors use microtubule tracks to move a variety of cargoes around cells—the movement of chromosomes along the mitotic spindle during mitosis is an example. Hirokawa (p. 519) describes the large number of microtubule-based motors, encoded by the kinesin and dynein multigene families, and elaborates on their roles in intracellular transport. A kinesin Web site has details on many of the aspects of the cell biology and biophysics of this important intracellular motor protein (http://www.blocks.fhcrc.org/ ~kinesin/). The actin cytoskeleton also shapes cellular processes; for example, in the formation of filopodia or cell contact sites. Hall (p. 509) looks at the interplay between actin architecture and the signal transduction machinery of the cell in promoting profound changes in cell shape and motility in response to extracellular signals. Less is known about the role of intermediate filaments in cells, mainly because of a lack of tools with which to study their assembly and disassembly. Fuchs and Cleveland (p. 514) summarize recent advances in our understanding of the roles of multiple types of intermediate filaments, which have become clear through the discovery of several diseases linked to intermediate filament pathology. A Research News story by Elizabeth Pennisi (p. 477) focuses on the kinetochore, the part of the chromosome that interacts with the microtubules of the mitotic spindle. Finally, Echard and co-workers (p. 580) describe a putative new motor that is likely to play a role in intracellular transport through the secretory pathway.

Problems with the cytoskeleton can cause disorders of the skin, the nervous system, and the muscles. Changes in the cytoskeleton are key, and even diagnostic, in the pathology of some diseases, including cancer. Understanding the basic cell biology of the cytoskeleton has contributed to our understanding of the pathology of some of these disorders and will continue to affect approaches to understanding, diagnosis, and therapy for various conditions.

Stella M. Hurtley

LETTERS

On balance

Calculation of the appropriate reference dose of mercury in fish is discussed. How to sort out what is causing deformities in North American frogs is said to be a possible "scientific nightmare." A group of physicists who are collaborating to produce high-en-

ergy gamma-ray beams defend their role in the project. And protein-protein and protein-lipid interactions



that "should greatly contribute to our understanding of the etiology of Alzheimer's disease" are explored.

Mercury in Fish

The Policy Forum "Balancing fish consumption benefits with mercury exposure" by Grace M. Egeland and John P. Middaugh (12 Dec., p. 1904) questions the wisdom of the Environmental Protection Agency's (EPA's) using our Iraqi data (1) to calculate their reference dose (Rfd), arguing that our Seychelles study (2) is more appropriate.

We agree. The Seychelles population is a more appropriate sentinel population for fish consumers in the United States: (i) the major source of methylmercury is open ocean fish, where the average concentrations are similar to those on the U.S. market, and (ii) the concentrations in hair are, on average, 10 to 20 times the average in the United States, because the Seychellois consume about 12 fish meals per week (3). Thus, any potential adverse effects of methylmercury in fish should be detected in the Seychelles long before such effects are seen in the United States.

The Policy Forum quotes our results for children up to 29 months of age. We now have findings for the same cohort tested at 66 months (4). We obtained tests scores of six different measures of child performance; general cognitive abilities, language ability, drawing and copying, pre-arithmetic achievement, letter word reading, and behavioral assessment. In all of these tests, no negative correlation with pre- or postnatal mercury levels was observed. To the contrary, the children performed at a level comparable to that of healthy, well-developed children in the United States.

The same examiner repeated in the Seychelles (5) exactly the same tests (neur-

ological and developmental milestones) that had been conducted in Iraq. Contrary to the Iraqi predictions, no adverse effects of methylmercury were detected.

The long-standing World Health Organization (WHO) guideline for a safe concentration of methylmercury intake is equivalent to a concentration in hair of 5 parts per million (ppm). The EPA Rfd would reduce this concentration by a factor of 4. The findings in the Seychelles study, where average hair concentrations were close to 7 ppm extending up to 26 ppm, support the longstanding WHO guideline.

Tom Clarkson Christopher Cox Philip W. Davidson Gary J. Myers Environmental Health Sciences Center, University of Rochester School of Medicine, Rochester, NY 14642, USA

References

- 1. C. Cox et al., Environ. Res. 49, 318 (1989).
- 2. P. W. Davidson et al., Neurotoxicology 16, 677 (1995).
- 3. C. F. Shamlaye et al., ibid., p. 597.
- G. Myers *et al.*, paper presented to the Mercury Panel of the U.S. Environmental Protection Agency Science Advisory Board, Washington, DC, February 1997.
- 5. G. Myers et al., Neurotoxicology 18, 819 (1997).

Egeland and Middaugh's Policy Forum discusses a timely topic for U. S. public health. I agree with their view that the RfD alone should not play a major role in risk assessment, because even Japan permits an RfD of 0.43 microgram per kilogram per day with a safety limit of 0.3 ppm based on an average fish consumption rate of 108.5 grams per day.

However, people in Alaska and Hawaii eat more fish on a daily basis compared to inhabitants of other states (1). Fish eaten by Alaskans is not so contaminated as that in 37 states which issued the fish consumption advisory because of mercury contamination. Therefore, Alaska's situation is exceptional. There is far more mercury contamination in other parts of the United States. First, the EPA indicated that fish in only 2% of the EPA-designated 370 sites in the United States exceeded the Food and Drug Administration's (FDA's) action level of 1 ppm (1). However, South Carolina alone has fish in 13 rivers exceeding the FDA action levels (2).

Second, although data from Seychelles islanders and Faroe islanders are valuable, it is too early to conclude what the effects of low-level methylmercury is on fetuses at this stage. Residents along the Shiranui Sea, of which Minamata Bay is a part, consumed fish (300 grams per day) containing relatively low levels of mercury (0.11 ppm) over a long period of time (at least 16 years) and developed Chronic Minamata Disease (CMD) symptoms later in their lives (3).

Last, it is estimated that 10,000 people in Japan are still suffering from delayed symptoms of CMD 41 years after the Minamata incident in Japan (4). CMD can not be explained by traditional dose-response or accumulation theories of metal poisoning (4, 5). I believe that it is time for U.S. public health officials to revisit the Minamata issue.

> Tomohiro Kawaguchi School of Public Health, University of South Carolina, Columbia, SC 29208, USA E-mail: tkawaguchi@sophe.sph.sc.edu

References

LETTERS

- "The mercury study report to Congress," Vol.1, "Executive summary" (Science Advisory Board draft review, U.S. Environmental Protection Agency, Washington, DC, 1966).
- The Gill Creek Watershed Project (Bureau of Water, South Carolina Department of Health and Environmental Control, Columbia, SC, 1997).
- T. Ninomiya, H. Ohmori, K. Hashimoto, K. Tsuruta, S. Ekino, *Environ. Res.* 70, 47 (1995).
- 4. M. Harada, *Crit. Rev. Toxicol.* **25**, 1 (1995).
- 5. B. Weiss, Neurotoxicology 17, 257 (1996).

Frog Deformities

Jocelyn Kaiser's article about the recent National Institute of Environmental Health Sciences "deformed frogs" workshop (News & Comment, 19 Dec., p. 2051) is the most accurate summary of this perplexing phenomenon I have yet read. However, a couple of points require clarification. First, a great deal of unnecessary confusion has been generated by the tendency to lump all amphibian deformities together. For example, cohorts of froglets with supernumerary limbs present a very different suite of characteristics than older metamorphosed frogs with missing limbs or limb parts, suggesting different causes, and most laboratory-induced deformities have shown little or no similarity to those seen in nature. Another point concerns whether deformities are on the rise or the scale of the problem has been overblown. An analysis of reports of deformities compiled by the North American Reporting Center for Amphibian Malformations (1) suggests the latter. Approximately half of the recent reports of deformed amphibians in the United States and Canada are from a single study (my own) of one site in California, published in 1990 (2)! More than half of the remaining deformed specimens are from intensive searches in Minnesota over the last 2 years. Furthermore, many recent reports may be questionable, for example, sightings of frogs with "retained tails."

Finally, numerous Web pages on de-

www.sciencemag.org • SCIENCE • VOL. 279

Throughput Minimum Time

PROTEIN

Maximum

CONCENTRATION

Ultrafree-®

Centrifugal Filter Devices let you concentrate or purify protein solutions in one quick and easy step. Even microliter amounts of material can be processed with minimal sample loss.

Choose from three devices:

Ultrafree-0.5 for concentrating up to 0.5 mL down to 20 μL in 10 min.*

Ultrafree-4 for concentrating up to 4 mL down to 50 µL in 15 min.*

Ultrafree-15 for concentrating up to 15 mL down to 300 μ L in 30 min.*

Each device incorporates the Biomax[™] (PES) membrane and a novel vertical design for fast concentration – without spinning to dryness. Sample recovery from the concentrate pocket or filtrate tube is convenient after a single spin.

Call or fax for more information. U.S. and Canada, call Technical Services: 1-800-MILLIPORE (645-5476). To place an order, call Fisher Scientific: 1-800-766-7000 (in Canada, call 1-800-234-7437). In Japan, call: (03) 5442-9716; in Asia, call: (852) 2803-9111; in Europe, fax: +33-3.88.38.91.95 *1 mg/ml Bovine Serum Albumin, Biomax-10

MILLIPORE

www.millipore.com/ultrafree e-mail: tech_service@millipore.com Circle No. 10 on Readers' Service Card